As of the latest Form 4 filed Jul 10, 2026.
What Edwards Lifesciences Corp insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 94 most recent filings for EW.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-10 | 2026-07-10 | Lippis Daniel J. CVP, TAVR | SSale | −619.00 | $91.70 | $56.8K | Yes (planned) | Form 4 ↗ |
| 2026-07-10 | 2026-07-10 | Lippis Daniel J., CVP, TAVR | MExercise | +619.00 | $72.68 | $45.0K | Yes (planned) | Form 4 ↗ |
| 2026-07-10 | 2026-07-09 | Mistras Theodora CVP, Chief Financial Officer | AAward | +12.3K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-07-10 | 2026-07-09 | Mistras Theodora, CVP, Chief Financial Officer | AAward | +87.6K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-07-07 | 2026-07-07 | Lippis Daniel J. CVP, TAVR | FTax | −377.00 | $95.18 | $35.9K | No | Form 4 ↗ |
| 2026-06-30 | 2026-06-30 | Lippis Daniel J. CVP, TAVR | SSale | −619.00 | $91.40 | $56.6K | Yes (planned) | Form 4 ↗ |
| 2026-06-30 | 2026-06-30 | Lippis Daniel J., CVP, TAVR | MExercise | +619.00 | $72.68 | $45.0K | Yes (planned) | Form 4 ↗ |
| 2026-06-17 | 2026-06-17 | Zovighian Bernard J CEO | SSale | −523.00 | $87.92 | $46.0K | Yes (planned) | Form 4 ↗ |
| 2026-05-29 | 2026-05-29 | Dahl Andrew M. SVP, Corporate Controller | SSale | −567.53 | $86.08 | $48.9K | No | Form 4 ↗ |
| 2026-05-27 | 2026-05-27 | BOBO DONALD E JR CVP,Strategy/Corp Development | SSale | −23.1K | $86.42 | $2.00M | No | Form 4 ↗ |
| 2026-05-22 | 2026-05-22 | Chopra Daveen CVP, TMTT & Surgical | SSale | −1.50K | $84.60 | $127K | No | Form 4 ↗ |
| 2026-05-18 | 2026-05-18 | Lippis Daniel J. CVP, TAVR | SSale | −620.00 | $81.14 | $50.3K | Yes (planned) | Form 4 ↗ |
| 2026-05-18 | 2026-05-18 | Lippis Daniel J., CVP, TAVR | MExercise | +620.00 | $72.68 | $45.1K | Yes (planned) | Form 4 ↗ |
| 2026-05-18 | 2026-05-15 | BOBO DONALD E JR CVP,Strategy/Corp Development | SSale | −8.00K | $81.82 | $655K | No | Form 4 ↗ |
| 2026-05-18 | 2026-05-15 | BOBO DONALD E JR, CVP,Strategy/Corp Development | SSale | −9.97K | $82.07 | $818K | No | Form 4 ↗ |
| 2026-05-12 | 2026-05-12 | Zovighian Bernard J CEO | SSale | −35.5K | $77.92 | $2.77M | Yes (planned) | Form 4 ↗ |
| 2026-05-12 | 2026-05-12 | Zovighian Bernard J, CEO | SSale | −845.00 | $78.40 | $66.3K | Yes (planned) | Form 4 ↗ |
| 2026-05-12 | 2026-05-12 | Zovighian Bernard J, CEO | GGift | +26.6K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-05-12 | 2026-05-12 | Zovighian Bernard J, CEO | GGift | −26.6K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-05-12 | 2026-05-11 | Zovighian Bernard J, CEO | FTax | −26.2K | $79.96 | $2.09M | Yes (planned) | Form 4 ↗ |
| 2026-05-12 | 2026-05-11 | Zovighian Bernard J, CEO | MExercise | +47.2K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-05-12 | 2026-05-11 | BOBO DONALD E JR CVP,Strategy/Corp Development | FTax | −7.47K | $79.96 | $597K | No | Form 4 ↗ |
| 2026-05-12 | 2026-05-11 | BOBO DONALD E JR, CVP,Strategy/Corp Development | MExercise | +13.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-12 | 2026-05-11 | Chopra Daveen CVP, TMTT & Surgical | FTax | −7.54K | $79.96 | $603K | No | Form 4 ↗ |
| 2026-05-12 | 2026-05-11 | Chopra Daveen, CVP, TMTT & Surgical | MExercise | +13.6K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-11 | 2026-05-11 | Ullem Scott B. CVP, Chief Financial Officer | FTax | −11.0K | $79.96 | $880K | No | Form 4 ↗ |
| 2026-05-11 | 2026-05-11 | Ullem Scott B., CVP, Chief Financial Officer | MExercise | +19.8K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-11 | 2026-05-11 | Markowitz Wayne CVP, JAPAC | SSale | −593.00 | $79.73 | $47.3K | No | Form 4 ↗ |
| 2026-05-11 | 2026-05-11 | Zovighian Bernard J CEO | GGift | +5.49K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-11 | 2026-05-11 | Zovighian Bernard J, CEO | GGift | −5.49K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-11 | 2026-05-11 | Lippis Daniel J. CVP, TAVR | FTax | −362.00 | $79.96 | $28.9K | No | Form 4 ↗ |
| 2026-05-11 | 2026-05-08 | Markowitz Wayne CVP, JAPAC | FTax | −226.00 | $82.76 | $18.7K | No | Form 4 ↗ |
| 2026-05-11 | 2026-05-08 | Zovighian Bernard J CEO | GGift | +4.22K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-11 | 2026-05-08 | Zovighian Bernard J, CEO | FTax | −5.40K | $82.76 | $447K | No | Form 4 ↗ |
| 2026-05-11 | 2026-05-08 | Zovighian Bernard J, CEO | GGift | −4.22K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-11 | 2026-05-07 | Markowitz Wayne CVP, JAPAC | FTax | −264.00 | $83.20 | $22.0K | No | Form 4 ↗ |
| 2026-05-11 | 2026-05-07 | Markowitz Wayne, CVP, JAPAC | AAward | +5.20K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-11 | 2026-05-07 | Zovighian Bernard J CEO | FTax | −4.15K | $83.20 | $346K | No | Form 4 ↗ |
| 2026-05-11 | 2026-05-07 | Zovighian Bernard J, CEO | AAward | +43.8K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-08 | 2026-05-08 | VALERIANI NICHOLAS J Director | AAward | +5.13K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-08 | 2026-05-08 | Sequeira Ramona Director | AAward | +3.25K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-08 | 2026-05-08 | LORANGER STEVEN R Director | AAward | +1.06K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-08 | 2026-05-08 | LORANGER STEVEN R, Director | AAward | +3.25K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-08 | 2026-05-08 | LAVIOLETTE PAUL A Director | AAward | +3.25K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-08 | 2026-05-08 | STONE HEISZ LESLIE Director | AAward | +3.25K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-08 | 2026-05-08 | GALLAHUE KIERAN Director | AAward | +1.06K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-08 | 2026-05-08 | GALLAHUE KIERAN, Director | AAward | +3.25K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-08 | 2026-05-08 | Feinberg David T Director | AAward | +3.25K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-08 | 2026-05-08 | BOBO DONALD E JR CVP,Strategy/Corp Development | FTax | −1.04K | $82.76 | $85.9K | No | Form 4 ↗ |
| 2026-05-08 | 2026-05-08 | Ullem Scott B. CVP, Chief Financial Officer | FTax | −1.66K | $82.76 | $137K | No | Form 4 ↗ |
| 2026-05-08 | 2026-05-08 | Davis Leslie C. Director | AAward | +3.25K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-08 | 2026-05-08 | Lippis Daniel J. CVP, TAVR | FTax | −450.00 | $82.76 | $37.2K | No | Form 4 ↗ |
| 2026-05-08 | 2026-05-08 | Dahl Andrew M. SVP, Corporate Controller | FTax | −289.00 | $82.76 | $23.9K | No | Form 4 ↗ |
| 2026-05-08 | 2026-05-08 | Chopra Daveen CVP, TMTT & Surgical | FTax | −1.14K | $82.76 | $94.4K | No | Form 4 ↗ |
| 2026-05-08 | 2026-05-08 | Bruls Annette CVP, EMEACLA | FTax | −84.00 | $82.76 | $6.95K | No | Form 4 ↗ |
| 2026-05-08 | 2026-05-07 | BOBO DONALD E JR CVP,Strategy/Corp Development | FTax | −831.00 | $83.20 | $69.1K | No | Form 4 ↗ |
| 2026-05-08 | 2026-05-07 | BOBO DONALD E JR, CVP,Strategy/Corp Development | AAward | +7.85K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-08 | 2026-05-07 | Ullem Scott B. CVP, Chief Financial Officer | FTax | −1.37K | $83.20 | $114K | No | Form 4 ↗ |
| 2026-05-08 | 2026-05-07 | Lippis Daniel J. CVP, TAVR | FTax | −309.00 | $83.20 | $25.7K | No | Form 4 ↗ |
| 2026-05-08 | 2026-05-07 | Lippis Daniel J., CVP, TAVR | AAward | +7.85K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-08 | 2026-05-07 | Dahl Andrew M. SVP, Corporate Controller | AAward | +3.02K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-08 | 2026-05-07 | Dahl Andrew M., SVP, Corporate Controller | AAward | +3.98K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-08 | 2026-05-07 | Chopra Daveen CVP, TMTT & Surgical | FTax | −674.00 | $83.20 | $56.1K | No | Form 4 ↗ |
| 2026-05-08 | 2026-05-07 | Chopra Daveen, CVP, TMTT & Surgical | AAward | +9.68K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-08 | 2026-05-07 | Bruls Annette CVP, EMEACLA | AAward | +6.65K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-05 | 2026-05-05 | Ullem Scott B. CVP, Chief Financial Officer | FTax | −11.1K | $82.91 | $923K | No | Form 4 ↗ |
| 2026-05-05 | 2026-05-05 | Ullem Scott B., CVP, Chief Financial Officer | MExercise | +13.0K | $59.26 | $770K | No | Form 4 ↗ |
| 2026-05-05 | 2026-05-05 | Zovighian Bernard J CEO | GGift | +523.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-05 | 2026-05-05 | Zovighian Bernard J, CEO | GGift | −523.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-05 | 2026-05-03 | Ullem Scott B. CVP, Chief Financial Officer | FTax | −620.00 | $83.98 | $52.1K | No | Form 4 ↗ |
| 2026-05-05 | 2026-05-03 | Zovighian Bernard J CEO | FTax | −515.00 | $83.98 | $43.2K | No | Form 4 ↗ |
| 2026-05-04 | 2026-05-04 | Lippis Daniel J. CVP, TAVR | SSale | −1.02K | $83.98 | $85.6K | Yes (planned) | Form 4 ↗ |
| 2026-05-04 | 2026-05-04 | Lippis Daniel J., CVP, TAVR | MExercise | +1.02K | $59.26 | $60.4K | Yes (planned) | Form 4 ↗ |
| 2026-05-04 | 2026-05-03 | Lippis Daniel J., CVP, TAVR | FTax | −252.00 | $83.98 | $21.2K | Yes (planned) | Form 4 ↗ |
| 2026-05-04 | 2026-05-03 | Chopra Daveen CVP, TMTT & Surgical | FTax | −282.00 | $83.98 | $23.7K | No | Form 4 ↗ |
| 2026-05-04 | 2026-05-03 | BOBO DONALD E JR CVP,Strategy/Corp Development | FTax | −469.00 | $83.98 | $39.4K | No | Form 4 ↗ |
| 2026-05-04 | 2026-05-01 | Lippis Daniel J. CVP, TAVR | SSale | −1.00K | $82.99 | $83.0K | Yes (planned) | Form 4 ↗ |
| 2026-05-04 | 2026-05-01 | Lippis Daniel J., CVP, TAVR | SSale | −19.00 | $83.99 | $1.60K | Yes (planned) | Form 4 ↗ |
| 2026-05-04 | 2026-05-01 | Lippis Daniel J., CVP, TAVR | MExercise | +1.02K | $59.26 | $60.4K | Yes (planned) | Form 4 ↗ |
| 2026-04-09 | 2026-04-09 | Ullem Scott B. CVP, Chief Financial Officer | SSale | −8.32K | $79.79 | $664K | Yes (planned) | Form 4 ↗ |
| 2026-04-09 | 2026-04-09 | Ullem Scott B., CVP, Chief Financial Officer | SSale | −4.68K | $80.50 | $376K | Yes (planned) | Form 4 ↗ |
| 2026-04-09 | 2026-04-09 | Ullem Scott B., CVP, Chief Financial Officer | MExercise | +13.0K | $59.26 | $770K | Yes (planned) | Form 4 ↗ |
| 2026-04-06 | 2026-04-06 | Lippis Daniel J. CVP, TAVR | SSale | −1.02K | $80.98 | $82.5K | Yes (planned) | Form 4 ↗ |
| 2026-04-06 | 2026-04-06 | Lippis Daniel J., CVP, TAVR | MExercise | +1.02K | $59.26 | $60.4K | Yes (planned) | Form 4 ↗ |
| 2026-03-11 | 2026-03-11 | Ullem Scott B. CVP, Chief Financial Officer | SSale | −7.90K | $85.21 | $673K | Yes (planned) | Form 4 ↗ |
| 2026-03-11 | 2026-03-11 | Ullem Scott B., CVP, Chief Financial Officer | SSale | −5.10K | $84.46 | $431K | Yes (planned) | Form 4 ↗ |
| 2026-03-11 | 2026-03-11 | Ullem Scott B., CVP, Chief Financial Officer | MExercise | +13.0K | $59.26 | $770K | Yes (planned) | Form 4 ↗ |
| 2026-03-11 | 2026-03-11 | Lippis Daniel J. CVP, TAVR | SSale | −1.02K | $85.38 | $87.0K | Yes (planned) | Form 4 ↗ |
| 2026-03-11 | 2026-03-11 | Lippis Daniel J., CVP, TAVR | MExercise | +1.02K | $59.26 | $60.4K | Yes (planned) | Form 4 ↗ |
| 2026-03-02 | 2026-03-02 | BOBO DONALD E JR CVP,Strategy/Corp Development | SSale | −11.3K | $85.93 | $974K | Yes (planned) | Form 4 ↗ |
| 2026-03-02 | 2026-03-02 | BOBO DONALD E JR, CVP,Strategy/Corp Development | MExercise | +11.3K | $59.26 | $672K | Yes (planned) | Form 4 ↗ |
| 2024-05-02 | 2024-05-02 | MUSSALLEM MICHAEL A Director | SSale | −17.1K | $84.59 | $1.45M | Yes (planned) | Form 4 ↗ |
| 2024-05-02 | 2024-05-02 | MUSSALLEM MICHAEL A, Director | SSale | −12.2K | $85.02 | $1.04M | Yes (planned) | Form 4 ↗ |
| 2024-05-02 | 2024-05-02 | MUSSALLEM MICHAEL A, Director | MExercise | +29.4K | $36.75 | $1.08M | Yes (planned) | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also EW’s full analysis or the market-wide insider trading feed. The tabs above jump to EW’s other SEC data.
Source: SEC Form 4 filings for EW, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.